Paper34812432
SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence.
Vargas-Herrera N and 5 others. Lancet Reg Health Am, 2022. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence. Papers, record 34812432. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34812432
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34075212 | SARS-CoV-2 variants, spike mutations and immune escape. | Nat Rev Microbiol | 2021 | https://conductscience.org/library/papers/34075212 | PubMed |
| 2 | 34022148 | Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. | Lancet Glob Health | 2021 | https://conductscience.org/library/papers/34022148 | PubMed |
| 3 | 33853970 | Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. | Science | 2021 | https://conductscience.org/library/papers/33853970 | PubMed |
| 4 | 33909850 | SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil. | Rev Inst Med Trop Sao Paulo | 2021 | https://conductscience.org/library/papers/33909850 | PubMed |
| 5 | 34370324 | Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern. | J Med Virol | 2021 | https://conductscience.org/library/papers/34370324 | PubMed |
| 6 | 33789086 | The variant gambit: COVID-19's next move. | Cell Host Microbe | 2021 | https://conductscience.org/library/papers/33789086 | PubMed |
| 7 | 34968415 | The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. | Cell Rep | 2022 | https://conductscience.org/library/papers/34968415 | PubMed |
| 8 | 33404586 | Genetic Variants of SARS-CoV-2-What Do They Mean? | JAMA | 2021 | https://conductscience.org/library/papers/33404586 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42424291 | Implementation of a SARS-CoV-2 genomic surveillance network as a strategy to face other health challenges in Peru. | Rev Peru Med Exp Salud Publica | 2026 | https://conductscience.org/library/papers/42424291 | PubMed |
| 41513994 | Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/41513994 | PubMed |
| 41018758 | Genomic surveillance of SARS-CoV-2 in the Andean Community (2020-2024): integrating regional sequencing efforts from Colombia, Ecuador, Peru, and Bolivia through "ORAS-CONHU" program. | Front Public Health | 2025 | https://conductscience.org/library/papers/41018758 | PubMed |
| 40333293 | Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40333293 | PubMed |
| 39166636 | Detection of SARS-CoV-2 variants in hospital wastewater in Peru, 2022. | Rev Peru Med Exp Salud Publica | 2024 | https://conductscience.org/library/papers/39166636 | PubMed |
| 38987406 | Early mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants in Chile. | Sci Rep | 2024 | https://conductscience.org/library/papers/38987406 | PubMed |
| 38907313 | Dispersion of SARS-CoV-2 lineage BA.5.1.25 and its descendants in Peru during two COVID-19 waves in 2022. | Genomics Inform | 2024 | https://conductscience.org/library/papers/38907313 | PubMed |
| 38900824 | The role of socio-economic disparities in the relative success and persistence of SARS-CoV-2 variants in New York City in early 2021. | PLoS Pathog | 2024 | https://conductscience.org/library/papers/38900824 | PubMed |
| 38473117 | Possible Spreading of SARS-CoV-2 from Humans to Captive Non-Human Primates in the Peruvian Amazon. | Animals (Basel) | 2024 | https://conductscience.org/library/papers/38473117 | PubMed |
| 38393135 | Genomic and Phylogenetic Characterisation of SARS-CoV-2 Genomes Isolated in Patients from Lambayeque Region, Peru. | Trop Med Infect Dis | 2024 | https://conductscience.org/library/papers/38393135 | PubMed |
| 38170049 | Predicting the spread of SARS-CoV-2 variants: An artificial intelligence enabled early detection. | PNAS Nexus | 2024 | https://conductscience.org/library/papers/38170049 | PubMed |
| 38045771 | Regional clustering and waves patterns due to COVID-19 by the index virus and the lambda/gamma, and delta/omicron SARS-CoV-2 variants in Peru. | Gates Open Res | 2022 | https://conductscience.org/library/papers/38045771 | PubMed |
| 37524331 | Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Peru. | Am J Trop Med Hyg | 2023 | https://conductscience.org/library/papers/37524331 | PubMed |
| 37376681 | The Lambda Variant in Argentina: Analyzing the Evolution and Spread of SARS-CoV-2 Lineage C.37. | Viruses | 2023 | https://conductscience.org/library/papers/37376681 | PubMed |
| 37322028 | Phylodynamic of SARS-CoV-2 during the second wave of COVID-19 in Peru. | Nat Commun | 2023 | https://conductscience.org/library/papers/37322028 | PubMed |
| 36935725 | Overview of the SARS-CoV-2 genotypes circulating in Latin America during 2021. | Front Public Health | 2023 | https://conductscience.org/library/papers/36935725 | PubMed |
| 36851324 | Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/36851324 | PubMed |
| 36848558 | Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/36848558 | PubMed |
| 36786950 | Evidence of natural selection and dominance of SARS-CoV-2 variant Lambda (C.37) over variants of concern in Cusco, Peru. | Arch Virol | 2023 | https://conductscience.org/library/papers/36786950 | PubMed |
| 36438034 | SARS-CoV-2 variants: Impact on biological and clinical outcome. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36438034 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34812432
GET https://conductscience.org/api/papers/v1/34812432/cited_by?page=2